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cdk = cyclin-dependent kinase; ER = oestrogen receptor; MAPK = mitogen-activated protein kinase; PR = progesterone receptor; PRA = short
form of the PR; PRB = long form of the PR; REA = repressor of oestrogen action.
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Introduction
The Hormones and Cancer 2000 Meeting was held in the
spectacular setting of Port Douglas on the North Queens-
land Coast, Australia, 3–8 November. The meeting com-
prised three plenary lectures and 11 sessions, two of
which were conjoint with the International Aromatase
Meeting being held at the same time. In addition to the oral
presentations, 50 posters were presented over two
lunchtime sessions. There were about 80 registrants for a
meeting that was possibly one of the most laid back that I
have ever attended, and where even the speakers wore the
uniform of shorts, T-shirts, thongs and umbrella required by
the rainy season of tropical North Queensland. Despite the
relaxed atmosphere, or possibly because of it, the presen-
tations and following discussions were of an extremely high
standard. This was also the only meeting that I have ever
attended that had a session devoted to a horse race! Yes,
we joined the rest of Australia in watching the Melbourne
Cup, which, for those who are interested, was won by
Brew with novice jockey Kerrin McEvoy on board.
Returning to the science, the meeting focused on recent
advances in breast and prostate cancer, with particular
emphasis on the role of steroids and steroid receptors in
the progression, treatment and prevention of tumours. The
speakers and their audience consequently encompassed
all disciplines, both scientific and clinical.
Steroid receptor co-regulators
Steroid receptor co-regulators were a major theme of the
meeting. There was a session devoted wholly to these
proteins and they put in several appearances at other sym-
posia, reflecting their emerging importance in hormonal
carcinogenesis, tumour progression, hormone resistance
and as therapeutic targets. The first plenary lecture was
given by Kathryn Horwitz (University of Colorado School
of Medicine, Denver, CO, USA), who presented data on
the role of steroid receptor co-activators and/or co-repres-
sors in mediating resistance to antagonists such as tamox-
ifen or the anti-progestin RU486. Using an elegant
strategy in which the ligand binding domain of the proges-
terone receptor (PR) linked to RU486 was used as bait in
a yeast two-hybrid assay, Professor Horwitz’ group iso-
lated the co-activator L7/SPA. This co-regulator not only
interacts with the PR, but more importantly also appears
to be involved in mediating the agonist effects of tamoxifen
on the oestrogen receptor (ER). Benita Katzenellenbogen
(University of Illinois and College of Medicine, Urbana, IL,
USA) used a similar strategy in isolating a protein known
as repressor of oestrogen action (REA). Like other co-
regulators, this REA protein contains the LXXLL motif
required for binding to steroid receptors and it inhibits
oestradiol–ER complex activity on several different oestro-
gen responsive promoters. Interestingly, the REA protein
can be prevented from interacting with, and thus inhibiting,
the ER by sequestration with prothymosin a (PTa) and it
may be no coincidence that PTa expression is high in
some breast tumours.
In the session devoted completely to receptor interacting
proteins, Michael Stallcup (University of Southern Califor-
nia, Los Angeles, CA, USA) and Malcolm Parker (Imperial
Cancer Research Fund, London, UK) both talked about
the p160 family of co-activators. Michael Stallcup showed
that all members of this family interact with the AF2 acti-
vating function of steroid receptors via a common LXXLL
Meeting report
Hormones and Cancer 2000
Elizabeth Anderson
Christie Hospital NHS Trust, Manchester, UK
Correspondence: Elizabeth Anderson, Head of Tumour Biochemistry Laboratory, Clinical Research Department, Christie Hospital NHS Trust,
Wilmslow Road, Manchester M20 4BX, UK. Tel: +44 161 446 3221; fax: +44 161 446 3211; e-mail: eanderson@picr.man.ac.uk
Received: 27 November 2000
Accepted: 30 November 2000
Published: 22 December 2000
Breast Cancer Res 2001, 3:118–121
© 2001 BioMed Central Ltd
(Print ISSN 1465-5411; Online ISSN 1465-542X)Available online http://breast-cancer-research.com/content/3/2/118
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
motif so there must be other mechanisms of introducing
specificity to the interactions, which may, in time, prove to
be targets for therapeutic intervention. Other data pre-
sented by Michael Stallcup suggested that p160 family
members might be ‘primary interacting proteins’ whose role
is to recruit secondary co-activators such as the histone
acetyltransferases or CBP/p300 to the hormone-activated
receptor. Malcolm Parker addressed the very important
question of how to examine the function of individual co-
activators without interference from endogenous co-regula-
tors. Accordingly, he introduced site-specific mutations into
various p160 family members such that they could interact
with a modified ER incapable of binding to endogenous
p160 proteins. This showed that oestrogen-dependent
transcription from reporter genes was dependent upon
direct recruitment of a p160 protein and that there was
functional redundancy among the p160 family. Professor
Parker then went on to emphasise that co-regulators such
as p160 can mediate ER interactions with other transcrip-
tional pathways. An important example is the cerbB2 gene
promoter, which is suppressed by the ER occupied by
oestradiol via the p160 co-activator.
Myles Brown (Dana-Farber Institute and Harvard Medical
School, Boston, MA, USA) demonstrated an ingenious
approach to determining which endogenous co-regulators
interact with steroid receptors and whether they interact in
a sequential, combinatorial or parallel manner. This
approach, known as chromatin immunoprecipitation,
allows analysis of endogenous co-factors that bind to
exogenous oestrogen-dependent promoter sequences
such as those of the pS2 and cathepsin D genes. This
analysis showed that, after oestradiol treatment, the ER
and several of the co-activators cycle on and off the pro-
moters in a precise order. For example, the promoter
starts to be occupied by ERa 15 min after the start of
treatment with occupation being maximal by 45 min, after
which the receptor cycles off. The co-activators AIB-1 and
PBP show the same pattern of movement on and off the
promoter but CBP and pCAF associate later after pol II
recruitment and histone acetylation has taken place. Even
more interestingly, treatment with tamoxifen induces
recruitment of the NCoR and SMRT co-repressors onto
the pS2 and cathepsin D promoter sequences in MCF-7
cultured breast cancer cells where the anti-oestrogen is a
pure antagonist. These data are in line with those pre-
sented by Kathryn Horwitz (University of Colorado School
of Medicine, Denver, CO, USA) in her plenary lecture sug-
gesting that tamoxifen sensitivity depends upon tumour
cell content of co-repressors such as NCoR and SMRT in
relation to co-activators.
Using this recently acquired knowledge of steroid recep-
tor co-regulators, Donald McDonnell (Duke University
Medical Center, Durham, NC, USA) and his group devel-
oped a novel strategy for finding compounds that disrupt
the interactions between ERa, ERb and their co-activa-
tors. This employs a combinatorial phage display
approach to identify small peptides that interact directly
with the receptors in the presence of oestradiol and that
block transcriptional activity. Clearly, the hope is that
these peptidomimetics can be developed into a new class
of more specific steroid receptor antagonists for the treat-
ment of breast and other hormone-dependent cancers.
Steroid receptor isoforms and structures in
relation to function
Another major theme of the conference was the characteri-
sation of receptor isoforms and their structures in relation
to function. The most dramatic discovery in recent years
has been that of a second oestrogen receptor, the ERb. It
now seems that ERa and ERb are often co-expressed and
that they can interact. In a breathtakingly comprehensive
plenary lecture, Jan-Åke Gustafsson (Karolinska Institute,
Huddinge, Sweden), expounded his ‘yin yang’ hypothesis
of ERa and ERb actions formulated after detailed analysis
of the phenotypes of mice in which the ERa and ERb
genes had been knocked out (ERKO and bERKO mice,
respectively). This hypothesis is that ERb acts to suppress
ERa action, and this is supported by the higher levels of
uterine and prostate proliferation seen in the bERKO mice
compared with wild type mice. There is considerable inter-
est in the existence of a separate endogenous ligand for
the ERb, and Professor Gustafsson suggested that it might
be 5a-androstane-3b,17b-diol (3b-ADIOL). This clearly
needs to be investigated further, as do the relative roles of
ERa and ERba in breast tumourigenesis and progression.
The group that generated the ERa or ERKO mice, and
subsequently collaborated in creating the bERKO mice,
was represented by Ken Korach (NIEHS/NIH, Research
Triangle Park, NC, USA). Professor Korach interestingly
described a slightly different phenotype for the bERKO
mice to that given by Professor Gustafsson in that they
were not able to identify any prostatic hyperplasias. In
further studies, the ERKO and bERKO mice were crossed
to obtain a double knockout or DERKO strain. The pheno-
type of the DERKO was equivalent, in many respects, to
that of the ERKO except for the ovaries, the appearance of
which differed significantly from either of the single knock-
outs implying that both oestrogen receptors are important
for the differentiation of this tissue.
Kathryn Horwitz completed her plenary lecture with some
new insights into the differential roles of the long (PRB)
and short (PRA) forms of the PR. Using cells that had
been engineered to express either PRA or PRB combined
with microarray technology, Professor Horwitz was able to
identify sets of genes regulated by progesterone via each
of the PR isoforms. Remarkably, there seemed to be very
little overlap between genes regulated by PRA and those
whose expression was influenced by PRB. ChristineBreast Cancer Research    Vol 3 No 2 Anderson
Clarke (Westmead Institute for Cancer Research, Sydney,
Australia) put this into a clinical context by showing that
the PRA and PRB isoforms were expressed in relatively
equal amounts in the normal breast and uterus. However,
this balance was altered in tumours such that they
expressed predominantly one form or the other. This dis-
ruption seemed, moreover, to be an early event in the
normal to malignant progression as it could be detected in
premalignant breast lesions such as atypical hyperplasia.
Using breast cancer cells engineered to overexpress one
or other of the PR isoforms, Dr Clarke also showed that
PRA overexpression was associated with changes in the
cytoskeleton and cell morphology that might contribute to
the malignant phenotype.
Another group interested in receptor variants and mutants
in premalignant breast lesions was that of Suzanne Fuqua
(Baylor College of Medicine, Houston, TX, USA), who
showed a mutation in the ERa gene to be present in 34%
of hyperplasias of usual type. The mutation, which involves
the border between the hinge and ligand binding domains
of the ERa, appears to confer increased sensitivity to
oestrogen, possibly by enhancing binding to SRC-1-type
co-activators at low levels of hormone.
Some beautiful crystallographic studies of the ERa and
ERb ligand binding domains occupied with a range of
agonists and antagonists were presented by Geoff
Greene (The Ben May Institute for Cancer Research,
Chicago, IL, USA), which emphasise further the impor-
tance of structural changes in receptor activation and inhi-
bition. These studies defined the interface between the
AF-2 activating function of the receptors and co-regula-
tors, and also showed how the position of helix 12 is
altered after binding of different agonists and antagonists.
These data go a long way toward explaining why drugs
such as tamoxifen have mixed antagonist/agonist effects,
and studies of this type should lead to the development of
new anti-steroidal compounds of improved specificity.
Consequences of oestrogen receptor
activation
Although a lot of time was devoted to how the oestrogen
and other steroid receptors are activated after ligand
binding, there were several presentations regarding the
more downstream consequences of this activation. Benita
Katzenellenbogen began by describing experiments in
which differential display was used to identify mRNAs
upregulated by anti-oestrogens. One such mRNA was that
for quinone reductase, the expression of which is
enhanced by anti-oestrogens and is repressed by oestra-
diol. Professor Katzenellenbogen speculated that
enhanced levels of enzymes such as quinone reductase
might afford protection against carcinogens and, thus,
would be suitable targets for novel breast cancer preven-
tion strategies.
One of the effects of treating hormone sensitive breast
cancer cells with oestradiol is increased entry from G0 to
the G1 phase of the cell cycle and acceleration of pro-
gression through G1. Professor Rob Sutherland and his
group (Garvan Institute of Medical Research, Sydney,
Australia) analysed the effects of oestrogen and anti-
oestrogens on the cyclin–cyclin-dependent kinase (cdk)
complexes known to be involved in controlling cell cycle
progression. Accordingly, treatment of cultured breast
cancer cells with specific anti-oestrogens such as ICI 164
384 or ICI 182 780 rapidly decreases c-myc and cyclin
D1 expression and, subsequently, the activity of the cyclin
D1–cdk4 complex. This, in turn, releases the p21CIP1
and p27KIP1 inhibitors of cdk activity so that they are free
to associate with and inhibit the activity of cyclin E–cdk2
complexes. This ultimately results in accumulation of
hypophosphorylated retinoblastoma protein, sequestration
of the E2F transcription factor and inhibition of G1 to S
phase progression. Subsequent oestradiol treatment of
anti-oestrogen arrested cells reverses these aforemen-
tioned changes, allowing G1 progression. Furthermore,
the effects of oestrogen treatment can be replicated by
increasing cellular content of c-myc or cyclin D1 via an
inducible promoter construct. It is only through painstak-
ing dissections of the mechanisms controlling cell cycle
progression such as these that we will begin to under-
stand the means by which oestrogens and anti-oestro-
gens exert their effects, and to understand how some
breast cancers become hormone resistant.
Cross talk between signalling pathways
It has become apparent in recent years that there is ‘cross
talk’ between the signalling pathways of the nuclear recep-
tors and those employed by receptors on the cell surface.
The significance of these interactions is, as yet, not clear,
but it seems possible that they contribute to processes
such as anti-oestrogen resistance. Joyce Slingerland (Sun-
nybrook and Women’s College Health Science Centre,
Toronto, Ontario, Canada) described interactions between
the ER and the mitogen-activated protein kinase (MAPK)
pathways in the control of p27KIP1 expression and activity.
This inhibitor of cyclin-dependent kinase activity, as already
mentioned, is critically involved in anti-oestrogen induced
breast cancer cell growth arrest. Accordingly, treatment
with oestradiol reduces breast cancer cell content of
p27KIP1, which de-represses cyclinE/cdk2 activity and
promotes cell cycle progression. It appears, however, that
oestradiol exerts its effects on p27KIP1 via both the ER
and the MAPK pathways. This conclusion was reached fol-
lowing experiments in which MAPK was shown to be very
rapidly activated by oestradiol treatment; indeed, the kinet-
ics of this activation suggest that oestradiol is acting by a
nongenomic route yet to be identified. At later time points,
however, the effects of oestradiol appear to be mediated
by the classical ER pathway. A role for MAPK in modulat-
ing anti-oestrogen sensitivity is suggested by experimentson the LY2 tamoxifen-resistant breast cancer cell line. The
MAPK pathway in these cells is constitutively activated,
and treatment with a specific MAPK kinase inhibitor
restores anti-oestrogen sensitivity. Further proof of princi-
ple was provided by an experiment in which a constitutively
active MAPK was introduced into hormone sensitive cells.
This reduced p27KIP1 content and produced partial anti-
oestrogen resistance. Several components of the MAPK
pathway are aberrantly expressed or activated in many
breast tumours, and this may be an important mechanism
of anti-oestrogen resistance.
The inhibitor of cdk activity p27KIP1 is an important
example of a protein whose expression and activity is
modulated by multiple signalling pathways including
steroid receptors. It now appears that steroid receptors
themselves are targets of other cell signalling cascades,
and Nancy Weigel (Baylor College of Medicine, Houston,
TX, USA) discussed the PR in this context. A number of
other signalling pathways converge on the PR to alter its
phosphorylation status, which can, in turn, enhance
agonist-dependent activity and even, in some cases,
induce antagonists to act as agonists. For example, acti-
vating the protein kinase A pathway by treating T47D
breast cancer cells with a cAMP analogue causes the anti-
progestin RU486 to act as an agonist. This has been
shown to be due to phosphorylation of PRB in particular,
and it is thought that this alteration reduces recruitment of
the NCoR and SMRT co-repressors to the antagonist-
occupied receptor. Using cells engineered to express
either PRA or PRB, Dr Weigel showed that components
of the MAPK pathway could also preferentially phosphory-
late and stimulate the activity of the PR isoforms. The PR
has multiple phosphorylation sites and the use of phos-
phorylation site-specific antibodies allows analysis of the,
sometimes, complex phosphorylation patterns. Interest-
ingly, serine 294 is one site that is a target of many of the
cell signalling pathways but there are significant differ-
ences in the kinetics of phosphorylation by these path-
ways. For example, activation of MAPK by epidermal
growth factor very rapidly phosphorylates Ser 294,
whereas steroid-dependent phosphorylation occurs more
slowly. Furthermore, although Ser 294 is common to both
PR isoforms, it is very poorly phosphorylated in the PRA in
vivo. Finally, it is not only steroid receptors, but also their
co-regulators that can be phosphorylated by protein
kinases. MAPK can phosphorylate the co-activator SRC-1,
and this can be blocked by an inhibitor of MAPK activa-
tion. Mutation of the MAPK-specific phosphorylation sites
substantially reduces the efficacy of SRC-1 as a co-activa-
tor. It thus appears that any number of cell signalling path-
ways can modulate nuclear receptor activity either directly
or indirectly by altering the activity of co-regulators.
It is becoming clear, having established that signals from
cell surface receptors can modulate steroid receptor
activity, that nuclear receptors can reciprocate. Bernd
Groner (Institute for Biomedical Research, Frankfurt,
Germany) described the interactions between the gluco-
corticoid receptor and stat5, a transcription factor that is
the downstream target for cytokine receptors including
those for growth hormone and prolactin. Activated GR
forms complexes with stat5, which then bind to the stat5
DNA binding site to enhance transcription of cytokine
inducible genes. What is interesting is that molecules such
as CBP/p300 and NCoR, previously identified on the basis
of their binding to nuclear receptors, also interact with
stat5; indeed, the amount of available CBP/p300 may be
the limiting factor in stat5 activation. Is it possible that
steroid receptor co-regulators will turn out to have a much
more universal role in the control of gene transcription?
Conclusions
Until recently, our models of steroid hormone signalling
through nuclear receptors were comparatively simple
affairs that did not really explain how antagonists such as
tamoxifen could act as agonists under certain circum-
stances. The Hormones and Cancer 2000 Meeting
demonstrated how far and how quickly our understanding
of steroid receptor action has progressed. Every aspect of
nuclear receptor signalling turns out to be more complex
than imagined, and there have been some real surprises,
including the discovery of a second ER, other steroid
receptor isoforms with distinct functions, the large number
and variety of co-regulatory molecules, and the mutual
interactions between steroid receptor signalling pathways
and those used by receptors on the cell surface. By eluci-
dating these complexities, we are beginning to arrive at
more satisfactory explanations for the dual nature of some
steroid antagonists. This report has focused on a few,
highly selected experimental areas but the Hormones and
Cancer Meeting actually covered topics from the bench to
the bedside and back again to give a full picture of how
research into basic mechanisms can be translated into
new more effective and specific treatments for breast and
other steroid-dependent cancers.
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